HIGHLIGHTS
- who: Po-Hsin Lee et al. from the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan have published the research: Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment, in the Journal: (JOURNAL)
- what: The authors aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI) particularly in those with resolved HBV infection. To evaluate the overall survival difference between TKI treatment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.